Search

everythinglearnresearchcommunity

for

Search:↓

Some breast cancer patients developed permanent hair loss after chemotherapy and hormonal therapy, showing patterns similar to common baldness and alopecia areata.

The study concluded that yellow dots are a common and useful sign for diagnosing alopecia areata in dark-skinned individuals and may indicate the severity of the condition.

New, safer treatments for children's hair disorders are needed, and better evaluation methods are recommended.

A patient with total hair loss developed vitiligo after using a treatment called DCP.

A breast cancer patient had lasting hair loss after chemotherapy, which improved with minoxidil treatment.

Trichoscopy is a useful tool for diagnosing patchy hair loss, reducing the need for biopsies.

People with common hair loss conditions may have a higher risk of heart disease and related health issues.

Nepalese patients with hair loss, especially women and those with androgenetic alopecia, experience a significant decrease in quality of life.

Blood vessel patterns in skin diseases relate to certain blood markers in systemic sclerosis but not in psoriasis or psoriatic arthritis, and may indicate circulation issues in alopecia.

A scalp biopsy can help confirm hair loss types when other methods don't provide a clear diagnosis.

Alopecia patients had similar element levels to normal people, except for differences in copper and low selenium.

Topical immunotherapy is the best treatment for severe alopecia areata.

Many children with alopecia areata also have other autoimmune diseases.

Low vitamin D can worsen pediatric alopecia areata.

Alopecia areata and lichen planus can occur together in children, which is important for diagnosis and treatment.

Immunosuppression therapy with methylprednisolone effectively treats childhood alopecia areata.

JAK inhibitors may help treat alopecia areata in children, but their safety needs careful evaluation.

Alopecia patients have a less active liver monoxygenase system, which can be treated with photochemotherapy and system inducers.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Most Korean systemic lupus erythematosus patients experienced hair loss, often as non-scarring diffuse hair loss, with non-scarring patch alopecia also common.

Most hair loss disorders can be accurately diagnosed and treated in an outpatient setting.

Adalimumab can cause hair loss and scalp issues in some psoriasis patients.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

The criteria help doctors diagnose and treat alopecia areata more effectively.

DPCP can help regrow hair in some people with severe alopecia.

Telemedicine is effective for diagnosing hair loss, especially in people with darker skin, during the pandemic.

Sintilimab treatment caused hair loss but led to complete tumor remission.

People with hair loss conditions may also have thyroid disorders, but more research is needed to understand the connection.